TipRanks Financial Blog In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Gossamer Bio (GOSS - Research Report), with a price target...\n more…
Seeking Alpha - Long Ideas Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss...\n more…
Zolmax Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Analysts at HC Wainwright boosted their Q3 2024 earnings per share estimates for Gossamer Bio in a research report issued on Thursday, August 29th...\n more…
Ticker Report Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Equities researchers at HC Wainwright increased their Q3 2024 earnings per share (EPS) estimates for Gossamer Bio in a research report issued on...\n more…
Business Wire Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...\n more…